Target antigen loss or modulation on tumor surfaces is a frequent mechanism of resistance following CD19 CAR-T or CD20 bispecific antibody failure. Dr. Budde highlights that treating relapsed patients with further targeted therapy without a biopsy frequently leads to treatment failure, as tumors often become CD19- or CD20-negative. Re-biopsying is vital to confirm target presence before initiating next-line therapies.
Clinicians often worry that steroid premedication or mitigation blunts the cytotoxic efficacy of bispecific antibodies. Dr. Budde points out that once T cells or CAR-T cells are fully activated, they become remarkably resistant to the immunosuppressive effects of steroids in both laboratory models and clinical practice, validating the safe use of steroids for toxicity management without compromising anti-tumor activity.
While prophylactic tocilizumab is standardly adopted to reduce CRS in multiple myeloma patients receiving BCMA-targeted bispecifics, it is unnecessary for CD20-targeted lymphoma bispecific antibodies. Due to differing tumor microenvironments and targets, CD20 bispecifics carry a distinct toxicity profile where routine tocilizumab prophylaxis provides no demonstrable clinical need, reserving the IL-6 inhibitor strictly for grade 2 or higher CRS.
Because bispecific antibody regimens are administered over numerous cycles (8 to 12 cycles or more), normal B cells are continually suppressed and cannot recover. This induces severe, persistent hypogammaglobulinemia. All patients receiving B-cell bispecifics require acyclovir prophylaxis for shingles, PJP prophylaxis if receiving steroids, and regular IVIG replacement therapy to avoid chronic sinus and upper respiratory tract infections.
Rather than viewing bispecific antibodies and CAR-T cell therapy as mutually exclusive, Dr. Budde uses bispecific combinations as an off-the-shelf bridging strategy. High tumor burden and refractory disease reduce CAR-T response rates; administering an initial truncated course of bispecific combinations debulks aggressive lymphoma into deep remissions before transitioning patients to single-infusion CAR-T to complete treatment.
Granulocyte colony-stimulating factor (G-CSF) should be temporarily withheld in patients experiencing unresolved cytokine release syndrome. G-CSF administration can independently trigger low-grade fevers and acute inflammatory symptoms, obscuring whether the patient's presentation is an escalating immune toxicity, infection, or standard drug side effect.
When utilizing the combination of polatuzumab vedotin and mosunetuzumab in aggressive lymphoma, sequencing matters. Giving polatuzumab vedotin first depletes circulating B cells prior to bispecific antibody exposure. Dr. Budde notes that debulking tumor burden and clearing circulating target cells in this manner significantly lowers the subsequent incidence and severity of cytokine release syndrome.
Clinicians often conflate bispecific cytokine release syndrome with CAR-T CRS, creating undue reluctance in community settings. Bispecific grade 1 CRS typically presents with mild fevers (around 101°F) that rarely escalate into high-grade fevers (103°F–104°F) seen in CAR-T. In most cases, bispecific grade 1 CRS is safely controlled in the outpatient setting with acetaminophen, ibuprofen, or a single dose of oral dexamethasone.
